Showing results (201-210 of 396) with videos related to
Sort By:
Pageof 40
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2017
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With TrametinibGeorgina V Long, Zeynep Eroglu, Jeffrey Infante, et al.Journal for Immunotherapy of Cancer|February 23, 2022
Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysisSiming Li, Xiaowen Wu, Xieqiao Yan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 26, 2006
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinomaMark J Ratain, Tim Eisen, Walter M Stadler, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2016
An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory MelanomaDanny N Khalil, Michael A Postow, Nageatte Ibrahim, et al.Journal of Translational Medicine|January 7, 2021
A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutationEster Simeone, Giosuè Scognamiglio, Mariaelena Capone, et al.Cancer Medicine|July 19, 2017
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation statusBenjamin Izar, William Sharfman, F Stephen Hodi, et al.Cancer Cell|March 16, 2016
Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma TherapyMichael P Smith, Holly Brunton, Emily J Rowling, et al.Oncoimmunology|May 4, 2018
A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanomaMeghan J Mooradian, Alexandre Reuben, Peter A Prieto, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2023
Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS TrialPaolo A Ascierto, Reinhard Dummer, Helen J Gogas, et al.Cancer Discovery|February 3, 2019
MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in BRAF-, NRAS-, and NF1-Mutant MelanomasOphélia Maertens, Ryan Kuzmickas, Haley E Manchester, et al.Pageof 40